-
Bandyopadhyay M, Morelli AE, Balmert SC, Ward NL, Erdos G, Sumpter TL, Korkmaz E, Kaplan DH, Oberbarnscheidt MH, Tkacheva O, Shufesky WJ, Falo LD, Larregina AT. Skin codelivery of contact sensitizers and neurokinin-1 receptor antagonists integrated in microneedle arrays suppresses allergic contact dermatitis. The Journal of allergy and clinical immunology. 2022 Jul;150(150). 114-130. NIHMSID: NIHMS1774119.
Abstract
Allergic contact dermatitis (CD) is a chronic inflammatory skin disease caused by type 1 biased adaptive immunity for which there is an unmet need for antigen (Ag)-specific immunotherapies. Exposure to skin sensitizers stimulates secretion of the proinflammatory neuropeptides substance P and hemokinin 1, which signal via the neurokinin-1 receptor (NK1R) to promote the innate and adaptive immune responses of CD. Accordingly, mice lacking the NK1R develop impaired CD. Nonetheless, the role and therapeutic opportunities of targeting the NK1R in CD remain to be elucidated.